Back to today’s briefing

Story perspectives

APOE ?4 Carriers Face Risks from Alzheimer's Treatments

2/27/2025

50 12

Summary

Story summary

Carriers of the APOE ?4 allele are at a heightened risk for negative reactions to anti-amyloid therapies, impacting their treatment options. Alzheimer's disease, characterized by amyloid-beta accumulation, is diagnosed through clinical assessments and biomarker tests. While promising drugs like lecanemab and donanemab can slow progression, they remain off-limits for those with homozygous ?4 due to safety worries.

1 of 1

Story summary

Carriers of the APOE ?4 allele are at a heightened risk for negative reactions to anti-amyloid therapies, impacting their treatment options. Alzheimer's disease, characterized by amyloid-beta accumulation, is diagnosed through clinical assessments and biomarker tests. While promising drugs like lecanemab and donanemab can slow progression, they remain off-limits for those with homozygous ?4 due to safety worries.